SPSB4: A Potential Drug Target and Biomarker (G92369)

Target Name: SPSB4

NCBI ID: G92369

SPSB4

SPSB4: A Potential Drug Target and Biomarker

Sodium channels play a crucial role in many biological processes, including muscle contractions, nerve function, and brain activity. They are also involved in pain perception and other physiological processes that are important for human well-being. The sodium channel SPSB4 (Sarco/P120 subunit beta) is a protein that is expressed in many different tissues and is involved in the regulation of sodium channels.

SPSB4 is a member of the P-type sodium channel subfamily, which is one of the largest families of sodium channels. P-type channels are involved in the rapid depolarization of the neuronal membrane that occurs during the initiation of an action potential. They are also involved in the regulation of neurotransmitter release and are thought to play a role in pain perception.

SPSB4 is expressed in a variety of tissues, including the brain, heart, and muscle. It is also involved in the regulation of ion channels in these tissues, which are critical for the proper functioning of these organs. For example, SPSB4 is involved in the regulation of the rapid depolarization that occurs during muscle contractions. This is important for maintaining muscle function and strength, as well as for allowing the body to respond quickly to changes in its environment.

SPSB4 is also involved in the regulation of ion channels in the brain, which are critical for the proper functioning of the brain. For example, SPSB4 is involved in the regulation of the rapid depolarization that occurs during the initiation of an action potential. This is important for the proper functioning of the nervous system, as well as for the regulation of pain perception.

In addition to its role in the regulation of sodium channels, SPSB4 is also involved in the regulation of other ion channels. For example, it is involved in the regulation of the calcium channels that are involved in muscle contractions and other physiological processes. It is also involved in the regulation of the potassium channels that are involved in the regulation of muscle activity and blood pressure.

SPSB4 is a potential drug target because of its involvement in the regulation of sodium channels and other ion channels. Its function as a drug target makes it an attractive target for the development of new treatments for a variety of neurological and psychiatric disorders. For example, SPSB4 may be a useful target for the treatment of epilepsy, as it is involved in the regulation of ion channels in the brain that are involved in the diagnosis of epilepsy. It may also be a useful target for the treatment of other neurological disorders, such as stroke and Alzheimer's disease.

In addition to its potential as a drug target, SPSB4 is also a potential biomarker. Its involvement in the regulation of sodium channels and other ion channels makes it an attractive target for the development of new diagnostic tests for a variety of neurological and psychiatric disorders. For example, SPSB4 may be used as a biomarker for the diagnosis of epilepsy, as it is involved in the regulation of ion channels in the brain that are involved in the diagnosis of epilepsy. It may also be used as a biomarker for other neurological disorders , such as stroke and Alzheimer's disease.

Overall, SPSB4 is a protein that is involved in the regulation of sodium channels and other ion channels in a variety of tissues. Its function as a drug target and biomarker makes it an attractive target for the development of new treatments for a variety of neurological and psychiatric disorders. Further research is needed to fully understand the role of SPSB4 in these processes and to develop new treatments based on its properties.

Protein Name: SplA/ryanodine Receptor Domain And SOCS Box Containing 4

Functions: Substrate recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:21199876, PubMed:15601820). Negatively regulates nitric oxide (NO) production and limits cellular toxicity in activated macrophages by mediating the ubiquitination and proteasomal degradation of NOS2 (PubMed:21199876). Acts as a bridge which links NOS2 with the ECS E3 ubiquitin ligase complex components ELOC and CUL5 (PubMed:21199876). Diminishes EphB2-dependent cell repulsive responses by mediating the ubiquitination and degradation of EphB2/CTF2 (PubMed:28931592). Regulates cellular clock function by mediating the ubiquitin/proteasome-dependent degradation of the circadian transcriptional repressor NR1D1 (PubMed:26392558)

The "SPSB4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPSB4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets